Drug Profile
Research programme: cannabinoid receptor modulators - Sumitomo Pharma America/IntelGenx
Alternative Names: CAT 210; CAT 320; INT 0014/2008; ModulynLatest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Cannasat Therapeutics
- Developer Cynapsus Therapeutics; IntelGenx Corp.
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Anxiety disorders; Major depressive disorder; Schizophrenia
Most Recent Events
- 25 Oct 2016 Cynapsus Therapeutics has been acquired by Sunovion Pharmaceuticals
- 31 Dec 2008 Preclinical trials in Schizophrenia in Canada (PO)
- 07 Nov 2006 Preclinical trials in Chemotherapy induced nausea and vomiting in Canada (Sublingual)